Analystreport

UroGen Pharma Ltd. (NASDAQ: URGN) had its price target lowered by analysts at HC Wainwright from $64.00 to $55.00. They now have a "buy" rating on the stock.

UroGen Pharma Ltd. - Ordinary Shares  (URGN) 
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com